Development of products for next-generation genetic testing equipment
First written in FY2016. 1 of 3 entries say "Softened", first in FY2017-Q1. Latest entry: FY2017-Q2.
No other company in this theme has enough history to compare yet.
- FY2017-Q2DroppedAnnual report
「During the second quarter of the current fiscal year, TrimGen Corporation, formerly a consolidated subsidiary, was excluded from the scope of consolidation after all of its shares were sold.」
After all shares of TrimGen Corporation were sold and it was excluded from the scope of consolidation, development of next-generation genetic testing products by the company was no longer described as an ongoing theme for the group. - FY2017-Q1SoftenedAnnual report
「TrimGen Corporation has required considerable time to develop next-generation products. A company has expressed interest in its technology, and the company is also considering its future direction.」
The disclosure now states that development of next-generation products is taking time and that the company's future direction remains under consideration. - FY2016First statedAnnual report
「TrimGen Corporation conducts research and development of genetic testing kits and gene extraction reagents for selecting anticancer drugs and controlling dosages of medications such as anticoagulants. It is currently developing products for next-generation genetic testing instruments capable of simultaneously analyzing multiple genes and large numbers of samples.」
Building on genetic testing kits and reagents, the company is developing products capable of simultaneously analyzing multiple genes and large numbers of samples.